Mineralized tissue cells are a principal source of FGF23

Bone

Volumn 40, Issue 6, 2007, Pages 1565-1573

  Yoshiko, Yuji ^a   Wang, Hua ^a   Minamizaki, Tomoko ^a   Ijuin, Chise ^b   Yamamoto, Ryoko ^a   Suemune, Setsuko ^a   Kozai, Katsuyuki ^a   Tanne, Kazuo ^a   Aubin, Jane E ^c   Maeda, Norihiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone cells; Cellular development; FGF23 expression; Mineralized tissue; Normal osteoblast; Tooth

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; GLYCEROL 2 PHOSPHATE; MESSENGER RNA; SODIUM PHOSPHATE COTRANSPORTER 2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BONE DEVELOPMENT; BONE MINERALIZATION; CALVARIA; CARTILAGE CELL; CELL CULTURE; CELL LABELING; CELL MATURATION; CEMENTUM; CONTROLLED STUDY; ENZYME INHIBITION; FEMUR; GERM CELL; IMMUNOREACTIVITY; INCISOR; MALE; NONHUMAN; ODONTOBLAST; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; TOOTH;

ANIMALS; BONE AND BONES; CELLS, CULTURED; FIBROBLAST GROWTH FACTORS; OSTEOBLASTS; RATS; RATS, WISTAR; SKULL; TOOTH;

EID: 34248512085     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.01.017     Document Type: Article

References (36)

1. Quarles L.D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J. Clin. Invest. 112 (2003) 642-646
2. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
3. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
4. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112 (2003) 683-692
5. Benet-Pages A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14 (2005) 385-390
6. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
7. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., and Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 278 (2003) 37419-37426
8. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 (2002) 3179-3182
9. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
10. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004) 409-414
11. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 (2004) 3087-3094
12. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
13. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004) 421-432
14. Yamashita T., Yoshioka M., and Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000) 494-498
15. Weber T.J., Liu S., Indridason O.S., and Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18 (2003) 1227-1234
16. Mirams M., Robinson B.G., Mason R.S., and Nelson A.E. Bone as a source of FGF23: regulation by phosphate?. Bone 35 (2004) 1192-1199
17. Bai X., Maio D., Panda D., Grady S., Mckee M.D., Goltzman D., et al. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol. Endocrinol. 16 (2002) 2913-2915
18. 3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. 289 (2005) G1036-G1042
19. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17 (2006) 1305-1315
20. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140 (1999) 4982-4987
21. Bellows C.G., Aubin J.E., Heersche J.N., and Antosz M.E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 38 (1986) 143-154
22. Akatsu T., Tamura T., Takahashi N., Udagawa N., Tanaka S., Sasaki T., et al. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J. Bone Miner. Res. 7 (1992) 1297-12306
23. Yoshiko Y., Maeda N., and Aubin J.E. Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. Endocrinology 144 (2003) 4134-4143
24. 2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J. Biol. Chem. 280 (2005) 24035-24042
25. Aubin J.E. Regulation of osteoblast formation and function. Rev. Endocr. Metab. Disord. 2 (2001) 81-94
26. Qin C., Baba O., and Butler W.T. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit. Rev. Oral. Biol. Med. 15 (2004) 126-136
27. Martin E.A., Ritman E.L., and Turner R.T. Time course of epiphyseal growth plate fusion in rat tibiae. Bone 32 (2003) 261-267
28. Marie P.J., Coffin J.D., and Hurley N.M. FGF and FGFR signaling in chondrodysplasia and craiosynostosis. J. Cell. Biochem. 96 (2005) 888-896
29. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281 (2006) 6120-6123
30. Kawaguchi H., Manabe N., Miyaura C., Chikuda H., Nakamura K., and Kuro-o M. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104 (1999) 229-237
31. Standal T., Borset M., and Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol. 26 (2004) 179-184
32. Beck Jr. G.R., and Knecht N. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J. Biol. Chem. 278 (2003) 41921-41929
33. Aubin J.E., Lain J.B., and Stein G.S. Bone formation: maturation and functional activities of osteoblast lineage cells. In: Favus M.J. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. (2006), The American Society for Bone and Mineral Research, Washington, DC, USA 20-29
34. Wu S., Yoshiko Y., and De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J. Biol. Chem. 281 (2006) 5120-5127
35. Chikazu D., Katagiri M., Ogasawara T., Ogata N., Shimoaka T., Takato T., et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J. Bone Miner. Res. 16 (2001) 2074-2081
36. Yu X., Ibrahimi O.A., Goetz R., Zhang F., Davis S.I., Garringer H.J., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 (2005) 4647-4656